Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901107 | 0.85 | MGLL (0.58) | MGLLLMNA | |
| SCHEMBL2945825 | 0.77 | MGLL (0.58) | MGLLMAPT | |
| SCHEMBL6607895 | 0.77 | MGLL (0.58) | MGLLKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL29952719 | 0.77 | MGLL (0.58) | MGLLMAPT | |
| SCHEMBL15191227 | 0.77 | MGLL (0.58) | MGLLTSHR | |
| SCHEMBL4283955 | 0.74 | MAPT (0.45) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8212 | 0.74 | MGLL (1.00) | MGLLAPPCA1CA2 | |
| SCHEMBL1612576 | 0.73 | MGLL (0.53) | MGLLAPP | |
| SCHEMBL2082708 | 0.73 | MGLL (0.53) | MGLLKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL225978 | 0.73 | MGLL (0.53) | MGLLMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4244213-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116745288-A | Compounds and uses thereof | 福霍恩治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022103899-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3365061-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (DE) | 2018-08-29 | — | — | EP | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017069980-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017069980-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | MGLL 4677/4885KDM4E 3856/4885MEN1 3100/4885 |
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | MGLL 3943/4885KDM4E 1848/4885MEN1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.